Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18842693 | 0.82 | RAB9A (0.32) | RAB9A | |
| SCHEMBL20614749 | 0.74 | NEK2 (0.31) | — | |
| SCHEMBL441487 | 0.71 | RAB9A (0.54) | CYP2D6RAB9A | |
| SCHEMBL4569231 | 0.69 | RAB9A (0.38) | RAB9A | |
| SCHEMBL10232882 | 0.68 | RAB9A (0.47) | RAB9A | |
| SCHEMBL9963290 | 0.68 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL20618139 | 0.68 | GRIN2D (0.35) | — | |
| SCHEMBL2603296 | 0.68 | CYP2D6 (0.45) | CYP2D6 | |
| SCHEMBL19606086 | 0.67 | RAB9A (0.36) | CYP2D6RAB9A | |
| SCHEMBL21249758 | 0.67 | CYP2D6 (0.37) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | CYP2D6 601/4885RAB9A 575/4885 |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | CYP2D6 601/4885RAB9A 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.